Nurses are often at the front lines of clinical care and as such, are perfectly positioned to bridge the gap between evolving clinical evidence and patient-centered care in Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma (MM). This dynamic educational activity will equip nursing professionals with the critical skills to integrate the latest advancements in CAR T-cell therapy into practice, ensuring alignment with NCCN guidelines and patient preferences. Through interactive case studies and expert-led discussions, you’ll be empowered to manage complex treatment scenarios, deliver comprehensive patient education, and navigate even the trickiest treatment-related challenges.
On May 15, 2024 (after the recording of this activity), the FDA has granted accelerated approval for lisocabtagene maraleucel, a CAR T-cell therapy, for the treatment of adult patients with R/R FL who have received two or more prior lines of systemic therapy.
On May 30, 2024 (after the recording of this activity), the FDA has granted accelerated approval for lisocabtagene maraleucel, a CAR T-cell therapy, for the treatment of adult patients with R/R MCL who have received after at least 2 lines of systemic therapy, including a BTK inhibitor
Speakers
Rayne H. Rouce, MD, BS
Associate Professor
Department of Pediatrics
Texas Children’s Cancer Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX
Rayne Rouce, MD, BS, is a Pediatric Hematologist and Oncologist at Texas Children's Cancer Center where she is a member of the Leukemia and Bone Marrow Transplant Programs.
She received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston, TX, then completed fellowship at Texas Children's Hospital. Dr. Rouce has spent the past several years of her career pioneering immunotherapy research for patients with refractory leukemia and lymphoma. Specifically, she works as part of a research program (The Center for Cell and Gene Therapy at Baylor College of Medicine) focused on translating targeted T cell therapies from the bench to bedside and has been involved in every aspect of CAR T cell development for clinical use. She has significant clinical experience in taking care of patients who have received CAR T cells and is passionate about ensuring patients and families understand this exciting new therapy.
Sanjay Sharma, MD
St. Jude Crosson Cancer Institute
Providence OC Cancer Institute
Fullerton, CA
Dr. Sanjay Sharma is a highly accomplished hematologist oncologist with 18 years of experience at St Jude Heritage Medical Group, Providence Health System, Fullerton, CA. He has held various leadership roles during his tenure, including serving as Director of the Crosson Cancer Institute and has peer-reviewed publications. He graduated from medical school at Virginia Commonwealth Univ, internal medicine residency at Washington University in St Louis and fellowship at Mt Sinai Hospital NYC where he was chief fellow. In addition to his work in the medical field, Dr. Sharma is founder of Ishash Inc, a medical education company, founder of Physician Real Estate Nation, and general principal in multifamily syndications. Dr. Sharma is known for his dedication to improving the lives of his patients and for his commitment to advancing medical education and research.
Laura J. Zitella, MS, RN, ACNP-BC
Nurse Practitioner
Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program
Associate Clinical Professor
University of California, San Francisco
San Francisco, CA
Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, is a nurse practitioner in the Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program and Associate Clinical Professor in the Department of Physiological Nursing at the University of California San Francisco. She earned her Master of Science from the University of Illinois in Chicago. Laura holds certifications as an Acute Care Nurse Practitioner and an Advanced Oncology Certified Nurse. Ms. Zitella is recognized as a national nurse practitioner leader and educator. Her clinical expertise includes the care of patients with lymphoma and multiple myeloma, survivorship and supportive care. She has delivered hundreds of educational presentations and authored numerous peer-reviewed publications, web courses, videos, and book chapters.
Accreditation and Disclosure Information
Target Audience
This activity is intended for academic and community nurses and NPs who treat and manage patients with Non-Hodgkin’s Lymphoma and Multiple Myeloma.
Educational Objectives
After completing this CE activity, the participant should be better able to:
- Describe the process of CAR T-cell therapy, including its manufacturing, administration, and mechanism of action in NHL and MM
- Align CAR T-cell therapy choices and new and emerging treatments, including bispecific antibodies and combination therapies (e.g., TCEs and CELMoD) with NCCN clinical guidelines, by incorporating the latest clinical evidence, drug mechanism of action, patient preferences, and disease subtypes for both NHL and MM
- Employ effective patient education in differentiating available treatment options, addressing clinical trial participation, and providing resources for patient/caregiver support
- Integrate strategies to identify and manage common treatment-emergent events and long-term toxicities related to CAR T-cell therapy
- Incorporate action-based plans to address challenges associated with transitioning CAR T-cell therapy to community practices and outpatient settings, thereby improving patient access
Agenda
- Keeping Current the Advances in NHL
- Supporting patients through the diversity of the disease (indolent vs aggressive disease)
- Keeping Current with Clinical Guidelines: Navigating CART in MM
- Supporting patients through clinical trial enrollment hesitations
- Optimizing Patient Outcomes: Managing NHL and MM TEAEs
- Addressing barriers to care through effective patient education
- The Future of CAR T-cell Therapy
- Strategies and perspectives for CAR T-cell therapy in community and outpatient settings
- Key Takeaways and Conclusions
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 1.5 contact hours in the area of pharmacology.
ILNA Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
*1.5 points: Oncologic Emergencies (OCN, CPHON, AOCNP); Oncology Nursing Practice (OCN); Pediatric Hematology and Oncology Nursing Practice (CPHON); Professional Practice/Performance (BMTCN, AOCNP); Quality of Life (BMTCN); Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP); Transplant Process and Infusion (BMTCN); Treatment (OCN, CBCN, AOCNP, CPHON)
*1.5 points: Care Continuum (OCN, CBCN, CPHON, AOCNP); Care of the Pediatric Hematology and Oncology Patient (CPHON); Cellular Collection, Preparative Regimens, and Infusion (BMTCN); Foundations of Transplant (BMTCN)
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing. Please also note that nurses’ individual learning plans are linked to their credential’s test blueprint (content outline). Current ONCC test content outlines can be found on the ONCC website:
OCN® | https://www.oncc.org/files/2022OCNOutline.pdf
CPHON® | https://www.oncc.org/files/CPHONTestContentOutline.pdf
CBCN® | https://www.oncc.org/files/2022CBCNOutline.pdf
BMTCN® | https://www.oncc.org/files/2022BMTCNOutline.pdf
AOCNP® | https://www.oncc.org/files/2020AOCNPTestContentOutline.pdf
Support Statement
This activity is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Rayne H. Rouce, MD, BS
Associate Professor of Pediatrics
Texas Children’s Cancer Center
Center for Cell and Gene Therapy
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX
Rayne H. Rouce, MD, BS, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Consultant/Advisor: Pfizer (ended 2/2022)
Research Funding: Tessa Therapeutics (funding to mentor, ended 5/2023)
Other: Honoraria: Novartis (ended 2/2024)
Planner/Presenter
Sanjay Sharma, MD
Hematologist-Oncologist
Providence St. Jude
Fullerton, CA
Sanjay Sharma, MD, has a financial interest/relationship or affiliation in the form of:
Speaker’s Bureau: Amgen, AstraZeneca, Bristol Myers Squibb, EMD Serono, Guardant
Planner/Presenter
Laura J. Zitella, MS, RN, ACNP-BC
Nurse Practitioner
Hematology, Blood and Marrow Transplant, and Cellular Therapy (HBC) Program
Associate Clinical Professor
University of California, San Francisco
San Francisco, CA
Laura J. Zitella, MS, RN, ACNP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: BeiGene
The following relationships have ended within the last 24 months:
Consultant/Advisor: AbbVie (ended February 2023)
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Requirements For Successful Completion
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and the activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact via email at mvu@mlieducation.org.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute, Inc | All Rights Reserved